New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 12, 2012
09:20 EDTSURGSynergetics growth trends may be poised to rebound, says Benchmark Co.
After Synergetics reported in-line Q1 EPS, Benchmark thinks the revenue of the company's previously weak Ophthalmic division appears to have stabilized. The firm expects the company's OEM business to continue to be strong and it maintains a Buy rating.
News For SURG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 5, 2015
17:02 EDTSURGValeant announces receipt of antitrust clearance for acquisition of Synergetics
Valeant Pharmaceuticals (VRX) announced that the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to the previously announced tender offer by its indirect wholly owned subsidiary, Blue Subsidiary Corp., for all of the outstanding shares of common stock of Synergetics USA (SURG) at a price per share of $6.50, net to the holder in cash, plus one contractual contingent value right per share, which represents the right to receive up to two contingent payments, if any, of up to $1.00 in the aggregate net to the holder in cash was granted early termination, effective October 5, by the U.S. Federal Trade Commission. The waiting period was scheduled to expire at 11:59 p.m., New York City time on October 7. The early termination of the HSR waiting period satisfies one of the conditions to consummate the tender offer. The completion of the tender offer remains subject to certain other conditions as described in the Tender Offer Statement on Schedule TO filed by Valeant on September 16, as amended. Subject to the satisfaction of the other conditions to closing, the transaction is expected to close in Q4.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use